文献速递关节外科

脂质体布比卡因对门诊手术中心全膝关节置换术后医疗资源利用、阿片类药物消耗及费用的真实世界影响

Real-World Impact of Treatment With Liposomal Bupivacaine on Health Care Resource Utilization, Opioid Consumption, and Cost Among Patients Undergoing Total Knee Arthroplasty in Ambulatory Surgical Settings in the United States.
PubMed 文献 · J Arthroplasty · 2025-10-17

该回顾性队列研究基于美国全国数据库,纳入2019年1月至2022年11月在门诊手术中心行全膝关节置换术的患者,经倾向评分匹配后每组2307例。结果显示,使用脂质体布比卡因(LB)的患者术后360天内阿片类药物治疗天数更少,术后30、90、360天全因及疼痛相关物理/作业治疗次数更少,总医疗费用更低。作者认为LB镇痛可作为多模式疼痛管理的一部分,可能改善门诊全膝关节置换术后的照护。

要点

  • 使用LB的患者术后360天内阿片类药物治疗天数平均为35.2天,未使用LB者为30.4天(P<0.05)。
  • 使用LB的患者术后30、90、360天全因物理/作业治疗次数分别为3.0、7.1、10.1次,均少于未使用LB者的3.5、8.1、11.6次(均P<0.01)。
  • 使用LB的患者术后30、90、360天总医疗费用分别较未使用LB者少247、438、1318美元(均P<0.05)。

核心结论

  • 术后LB镇痛与术后一年内更少的阿片类药物治疗天数、更低的总医疗资源利用和费用相关。
  • 作者认为这些结果可能进一步帮助医疗提供者了解LB镇痛作为多模式疼痛管理的一部分在改善门诊手术中心全膝关节置换术后照护中的作用。

研究设计与样本

  • 回顾性研究,从全国数据库识别2019年1月至2022年11月在门诊手术中心行全膝关节置换术且LB使用量为中高叶素的患者。
  • 根据手术当日是否使用LB分为两组,采用1:1倾向评分匹配创建均衡队列,匹配后每组2307例,平均年龄69岁,女性占60.3%。
  • 考察术后30、90、360天的阿片类药物使用、全因及疼痛相关医疗资源利用和费用。

主要发现

  • 术后360天内,使用LB的患者阿片类药物治疗天数平均为35.2天,未使用LB者为30.4天(P<0.05)。
  • 术后30、90、360天,使用LB的患者全因物理/作业治疗次数分别为3.0、7.1、10.1次,未使用LB者分别为3.5、8.1、11.6次(均P<0.01),疼痛相关物理/作业治疗次数趋势一致(均P<0.01)。
  • 术后30、90、360天,使用LB的患者总医疗费用分别较未使用LB者少247、438、1318美元,疼痛相关费用趋势相似(均P<0.05)。

临床怎么用

  • 原文结论指出,术后LB镇痛与术后一年内更少的阿片类药物治疗天数、更低的总医疗资源利用和费用相关。
  • 作者认为这些结果可能进一步帮助医疗提供者了解LB镇痛作为多模式疼痛管理的一部分在改善门诊手术中心全膝关节置换术后照护中的作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perioperative pain management is critical to postsurgical recovery, as inadequate control can adversely affect patients for years. With the rise of total knee arthroplasty (TKA) in ambulatory surgery centers (ASCs), evaluating real-world strategies for postoperative analgesia has become increasingly important. The aims of this study were to (1) compare postoperative opioid use between patients receiving liposomal bupivacaine (LB) versus those who did not; (2) evaluate LB's effect on outpatient physical therapy visits and health care utilization; and (3) quantify differences in pain-related health care costs. METHODS: Patients undergoing TKA in an outpatient ASC with moderate-to-high volume LB use between January 2019 and November 2022 were retrospectively identified from a national database. Patients were placed into two cohorts based on LB use on the TKA procedure date. Propensity score matching (PSM) with 1:1 matching created balanced cohorts. After PSM, each cohort comprised 2,307 patients (mean age of 69 years; 60.3% women). Opioid usage, all-cause and pain-related health care resource utilization (HCRU), and costs were examined over 30, 90, and 360 days postsurgery. RESULTS: On average, patients treated with LB had fewer opioid-treated days over 360 days postsurgery than those who did not have LB (35.2 versus 30.4; P < 0.05). Patients who had LB had fewer all-cause physical and occupational therapy (PT/OT) visits than patients who did not have LB over 30 (3.0 versus 3.5, P < 0.01), 90 (7.1 versus 8.1, P < 0.01), and 360 days (10.1 versus 11.6, P < 0.01) postsurgery, with consistent trends for pain-related PT/OT visits (all P < 0.01). Patients with LB incurred significantly lower total health care costs of $247, $438, and $1,318 less over 30, 90, and 360 days postsurgery, respectively, with similar trends for pain-related costs (all P < 0.05). CONCLUSIONS: Postsurgical LB analgesia was associated with fewer opioid-treated days and lower total HCRU and costs over one year after surgery. These results may further inform health care providers of the role of LB analgesia as part of multimodal pain management in improving postsurgical care following TKA in ASCs.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Lin JH, Huo T, Pandya S, et al. Real-World Impact of Treatment With Liposomal Bupivacaine on Health Care Resource Utilization, Opioid Consumption, and Cost Among Patients Undergoing Total Knee Arthroplasty in Ambulatory Surgical Settings in the United States. J Arthroplasty. 2025. PMID: 41110644. doi:10.1016/j.arth.2025.10.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。